Normaloe (Loperamide Hydrochloride)

Loperamide Hydrochloride, the active ingredient in Normaloe, is an opioid receptor agonist presented as an oral tablet for oral use. It treats acute and chronic diarrhea as well as irritable bowel syndrome with diarrhea in adults.

GNH USA supplies Normaloe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Normaloe, an opioid receptor agonist, is used to manage conditions characterized by excessive intestinal motility and fluid loss.

Acute diarrhea: reduces stool frequency and liquidity, helping restore normal bowel function. Chronic diarrhea: maintains stool consistency and limits daily bowel movements. Irritable bowel syndrome with diarrhea: alleviates diarrheal episodes and improves quality of life.

Loperamide Hydrochloride is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Constipation - Abdominal cramps or discomfort - Nausea - Dizziness - Dry mouth - Headache

Serious or Rare Side Effects: - Severe constipation leading to bowel obstruction - Paralytic ileus - Allergic reactions such as rash, angioedema, or anaphylaxis - Toxic megacolon, especially in infectious diarrheas - Cardiac arrhythmias, including QT prolongation, in susceptible individuals

When using Normaloe, consider the following safety measures.

Dosage adjustment: use lower doses in patients with hepatic impairment. Avoid use: in individuals with known hypersensitivity to loperamide. Caution: not recommended for infectious diarrheas caused by Clostridioides difficile. Pregnancy and lactation: consult a healthcare professional; safety has not been established. Drug interactions: review concomitant medications that may affect cardiac QT interval. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Loperamide may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid): - Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole) may increase loperamide plasma levels. - Co‑administration with other opioid agonists can cause additive central nervous system depression. - Use with QT‑prolonging agents (e.g., quinidine) may raise the risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP2C8 inhibitors (e.g., gemfibrozil) may modestly elevate loperamide concentrations. - Anticholinergic drugs may enhance constipation, requiring dose adjustment or monitoring.